Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C

HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genet...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 54; no. 4; pp. 256 - 264
Main Authors Pawlotsky, Jean-Michel, Pellerin, Muriel, Bouvier, Magali, Roudot-Thoraval, Françoise, Germanidis, Georgios, Bastie, Anne, Darthuy, Françoise, Rémiré, Jocelyne, Soussy, Claude-James, Dhumeaux, Daniel
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 01.04.1998
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
Abstract HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)‐single‐strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 ± 2.3 vs. 4.7 ± 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non‐responders (4.0 ± 1.7 vs. 5.4 ± 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti‐HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti‐HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C. J. Med. Virol. 54:256–264, 1998. © 1998 Wiley‐Liss, Inc.
AbstractList HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 plus or minus 2.3 vs. 4.7 plus or minus 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 plus or minus 1.7 vs. 5.4 plus or minus 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C.
HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 +/- 2.3 vs. 4.7 +/- 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 +/- 1.7 vs. 5.4 +/- 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P &lt; 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P &lt; 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis.
HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)‐single‐strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 ± 2.3 vs. 4.7 ± 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non‐responders (4.0 ± 1.7 vs. 5.4 ± 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti‐HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti‐HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis C. J. Med. Virol. 54:256–264, 1998. © 1998 Wiley‐Liss, Inc.
HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is subjected to strong selective pressure from neutralizing antibodies. The genetic complexity of this region is defined as the total number of genetic variants within the quasispecies population. The genetic complexity of the HVR1 region was examined in patients with chronic hepatitis C and its relationship with the epidemiology of HCV infection, and its influence on liver disease and the response to interferon treatment were determined in 114 patients with chronic hepatitis C. The genetic complexity of the HVR1 major variants was measured before treatment by using a polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) technique, and was compared with epidemiological, clinical, virological and histological features. The patients were treated with 3 megaunits of interferon (IFN) alfa for 3 to 6 months and the response to treatment was assessed at 3, 6 and 12 months. The HVR1 could be studied in 101 of the 114 patients (89%). Genetic complexity was significantly higher in patients infected through blood transfusion than intravenous drug use (mean complexity index: 5.7 +/- 2.3 vs. 4.7 +/- 1.5, respectively; P = 0.04). This relationship was independent of age and the estimated time since infection. No significant relationship was found with other parameters of infection or liver disease. In univariate analysis, the genetic complexity of HVR1 major variants did not affect the rates of ALT normalization at months 3 and 6 of IFN treatment. HVR1 genetic complexity was lower in patients with a sustained virological response than in non-responders (4.0 +/- 1.7 vs. 5.4 +/- 2.0, respectively; P = 0.07). In multivariate analysis of pretreatment parameters associated with a sustained virological response to treatment, three parameters appeared to be independent predictors of such a response: a low viral load (P < 0.04), a low anti-HCV core IgM titer (P = 0.03) and a low genetic complexity of HVR1 major variants (P < 0.04). In conclusion, the HVR1 of HCV has a quasispecies distribution in infected individuals. Its genetic complexity is significantly higher in transfusion recipients than in intravenous drug users, suggesting that the size of the initial inoculum affects the later emergence and development of viral quasispecies. The genetic complexity of HVR1, together with viral load and the anti-HCV IgM titer, are independent predictors of a sustained virological response to IFN alfa in patients with chronic hepatitis.
Author Bouvier, Magali
Soussy, Claude-James
Pawlotsky, Jean-Michel
Dhumeaux, Daniel
Roudot-Thoraval, Françoise
Pellerin, Muriel
Bastie, Anne
Rémiré, Jocelyne
Germanidis, Georgios
Darthuy, Françoise
Author_xml – sequence: 1
  givenname: Jean-Michel
  surname: Pawlotsky
  fullname: Pawlotsky, Jean-Michel
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 2
  givenname: Muriel
  surname: Pellerin
  fullname: Pellerin, Muriel
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 3
  givenname: Magali
  surname: Bouvier
  fullname: Bouvier, Magali
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 4
  givenname: Françoise
  surname: Roudot-Thoraval
  fullname: Roudot-Thoraval, Françoise
  organization: Department of Epidemiology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 5
  givenname: Georgios
  surname: Germanidis
  fullname: Germanidis, Georgios
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 6
  givenname: Anne
  surname: Bastie
  fullname: Bastie, Anne
  organization: Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 7
  givenname: Françoise
  surname: Darthuy
  fullname: Darthuy, Françoise
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 8
  givenname: Jocelyne
  surname: Rémiré
  fullname: Rémiré, Jocelyne
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 9
  givenname: Claude-James
  surname: Soussy
  fullname: Soussy, Claude-James
  organization: Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
– sequence: 10
  givenname: Daniel
  surname: Dhumeaux
  fullname: Dhumeaux, Daniel
  organization: Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris XII, Créteil, France
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2258420$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/9557291$$D View this record in MEDLINE/PubMed
BookMark eNqFUt1u0zAYjdDQ6AaPgOQLhNqLDP_FScqENAX6gwaVxijcfXIchxrSJNjptj4nL4RDS0ECaVeWfY7POfq-cxIc1U2tg-Cc4DOCMX0x_DDP5iOCUxGmOCZDkqYJ5qOIj_k5jcR4fDF_Hb59t-Sv2Bk-yxYvacgeBIPDh6NggAkXoRAkehScOPcVY5yklB4Hx2kUxTQlg-DHVNe6MwqpZt1W-s50W9SUqFtptNq22t5Ia2ReaWT1F9PUiKDhbHlFRj1ppVvZmc44lKEbYzfOY9lyNEbzuqw2ulYa-R-9lFpJK1WnrXHey_12MHWpVdfLyrrwDq5taqcd6hoPeXapbY9VpezpVrZb_456U113Dt2abuWlPcfn_yvM4-BhKSunn-zP0-Dj5M11NgsvF9N5dnEZKhYzHhZ5LpSOEhzTQgosmCxSmUjOc-lHWJIiViKnqowjISUXUkRxXhRY4aTAnBYJOw2e73Rb23zfaNfB2jilq0rWutk4iNOEUD_8e4lEsJTRRHji9Y6obOOc1SW01qyl3QLB0JcCoC8F9DuGfsewKwVEHDj4UgD4UkBfCmCAIVsABeZln-79N_laFwfRfQs8_myPS6f8uK2slXEHGqVRwin-k-7WVHr7T7R7kv0n2K-7lw13sr4c-u4gK-03EDGLI_j0fgqfGcOT2VUCE_YTRmPyaA
CODEN JMVIDB
Cites_doi 10.1002/hep.510240507
10.1128/AAC.40.2.320
10.1128/JVI.66.5.3225-3229.1992
10.1182/blood.V85.7.1681.bloodjournal8571681
10.1073/pnas.91.16.7792
10.7326/0003-4819-122-3-199502010-00002
10.1099/0022-1317-75-6-1361
10.1099/0022-1317-74-6-1093
10.1002/hep.1840200605
10.1002/hep.1840160302
10.1056/NEJM198612183152503
10.1002/hep.1840200504
10.1056/NEJM198911303212202
10.1016/0888-7543(89)90129-8
10.1128/JCM.33.7.1870-1874.1995
10.1099/0022-1317-76-7-1763
10.1002/(SICI)1096-9071(199607)49:3<242::AID-JMV14>3.0.CO;2-E
10.1099/0022-1317-76-4-881
10.1128/JCM.32.5.1357-1359.1994
10.1016/0016-5085(95)90452-2
10.1093/infdis/171.6.1607
10.1016/0168-8278(90)90075-3
10.7326/0003-4819-123-8-199510150-00008
10.1073/pnas.89.8.3468
10.1007/978-3-642-77011-1_1
10.1001/archderm.1995.01690220091017
10.1002/jmv.1890460103
10.1093/infdis/171.6.1619
10.1093/infdis/174.1.1
10.1002/hep.1840220406
10.1016/0016-5085(94)90770-6
10.1016/0027-5107(93)90209-X
10.1073/pnas.91.11.4821
10.1128/JCM.34.4.901-907.1996
ContentType Journal Article
Copyright Copyright © 1998 Wiley‐Liss, Inc.
1998 INIST-CNRS
Copyright_xml – notice: Copyright © 1998 Wiley‐Liss, Inc.
– notice: 1998 INIST-CNRS
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U9
8FD
FR3
H94
P64
RC3
7X8
DOI 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Genetics Abstracts
Virology and AIDS Abstracts
Engineering Research Database
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1096-9071
EndPage 264
ExternalDocumentID 10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3
9557291
2258420
JMV4
ark_67375_WNG_X330FHR8_F
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAVGM
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHUG
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEQTP
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFVGU
AFZJQ
AGJLS
AHBTC
AHMBA
AI.
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AITYG
HGLYW
OIG
08R
AAUGY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U9
8FD
FR3
H94
P64
RC3
7X8
ID FETCH-LOGICAL-c3734-dbb6ce58072da6063ad9a8a44ba096f1d7c6b2cf756aa46a657bdd0c08d042d83
IEDL.DBID DR2
ISSN 0146-6615
IngestDate Fri Aug 16 21:51:00 EDT 2024
Sat Aug 17 03:21:23 EDT 2024
Fri Aug 23 00:17:44 EDT 2024
Sat Sep 28 07:40:28 EDT 2024
Sun Oct 29 17:09:53 EDT 2023
Sat Aug 24 00:56:13 EDT 2024
Wed Jan 17 04:59:33 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Genetic variability
RNA
Alpha interferon
Cytokine
Hepatic disease
Hypervariable region
Infection
Virus
Chemotherapy
Treatment
Viral disease
Molecular epidemiology
Digestive diseases
Antiviral
Flaviviridae
Hepatitis C virus
Hepacivirus
Viral hepatitis C
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3734-dbb6ce58072da6063ad9a8a44ba096f1d7c6b2cf756aa46a657bdd0c08d042d83
Notes ArticleID:JMV4
istex:A836BC00AED8147B42C0DE9C0574D063B8E03786
ark:/67375/WNG-X330FHR8-F
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 9557291
PQID 16393286
PQPubID 23462
PageCount 9
ParticipantIDs proquest_miscellaneous_79812615
proquest_miscellaneous_16393286
crossref_primary_10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3
pubmed_primary_9557291
pascalfrancis_primary_2258420
wiley_primary_10_1002_SICI_1096_9071_199804_54_4_256_AID_JMV4_3_0_CO_2_3_JMV4
istex_primary_ark_67375_WNG_X330FHR8_F
PublicationCentury 1900
PublicationDate April 1998
PublicationDateYYYYMMDD 1998-04-01
PublicationDate_xml – month: 04
  year: 1998
  text: April 1998
PublicationDecade 1990
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: New York, NY
– name: United States
PublicationTitle Journal of medical virology
PublicationTitleAlternate J. Med. Virol
PublicationYear 1998
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Liss
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Liss
References Gumber SC, Chopra S: (1995): Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Annals of Internal Medicine 123: 615-620.
Pawlotsky JM, Fleury A, Choukroun V, Deforges L, Roudot-Thoraval F, Aumont P, Duval J, Dhumeaux D: (1994): Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. Journal of Clinical Microbiology 32: 1357-1359.
Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S: (1995): Pretreatment HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 22: 1050-1056.
Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T: (1994): Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20: 1121-1130.
Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Rémiré J, Métreau JM, Zafrani ES, Duval J, Dhumeaux D: (1996b): Factors affecting treatment responses to interferon-a in chronic hepatitis C. Journal of Infectious Diseases 174: 1-7.
Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, DiBisceglie AM, Peters M, Waggoner JG, Park Y, Jones EA: (1986): Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine 315: 1575-1578.
Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C: (1995): Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22: 30-35.
Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D: (1995c): Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases 171: 1607-1610.
Orita M, Suzuki Y, Sekiya T, Hayashi K: (1989): Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879.
Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: (1994): Genotypic analysis of hepatitis C virus in American patients. Hepatology 20: 1405-1411.
Pawlotsky JM, Hovanessian AG, Roudot-Thoraval F, Robert N, Bou-vier M, Babany G, Duval J, Dhumeaux D: (1996a): Effect of alpha interferon (IFN-a) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-a. Antimicrobial Agents and Chemotherapy 40: 320-324.
Holland JJ, De La Torre JC, Steinhauer DA: (1992): RNA virus populations as quasispecies. Current Topics in Microbiology and Immunology 176: 1-20.
Lu M, Funsch B, Wiese M, Roggendorf M: (1995): Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis. Journal of General Virology 76: 881-887.
Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Yahia M Ben, André C, Voisin MC, Intrator L, Zafrani ES, Duval J, Dhumeaux D: (1995b): Extra-hepatic immunological manifestations in chronic hepatitis C and hepatitis C virus serotypes. Annals of Internal Medicine 122: 169-173.
Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ: (1994): RNA virus quasispecies: significance for viral disease and epidemiology. Infectious Agents and Disease 3: 201-214.
Odeberg J, Yun Z, Sönnerborg A, Uhlen M, Lundeberg J: (1995): Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. Journal of Clinical Microbiology 33: 1870-1874.
Alter HJ: (1995): To C or not to C: these are the questions. Blood 85: 1681-1695.
Hopf U, Möller B, Küther D, Stemerowicz R, Lobeck H, Lüdtke-Handjery, Walter E, Blum HE, Roggendorf M, Deinhardt F: (1990): Long term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). Journal of Hepatology 10: 69-76.
Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J: (1992): Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCgenome distribution. Journal of Virology 66: 3225-29.
Sekiya T: (1993): Detection of mutant sequences by single-strand conformation polymorphism analysis. Mutation Research 288: 79-83.
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: (1989): Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321: 1494-1500.
Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T: (1996): The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 24: 1018-1023.
Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S: (1992): The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16: 619-624.
Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH: (1994): Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proceedings of the National Academy of Sciences USA 91: 7792-7796.
Lin HJ, Siwak EB, Lauder IJ, Hollinger FB: (1995): Single-strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologic cultures. Journal of Infectious Diseases 171: 1619-1622.
Weiner AJ, Geysem HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchison J, Houghton M: (1992): Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants : potential role in chronic HCV infections. Proceedings of the National Academy of Sciences (USA) 89: 3468-3472.
Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J: (1994): The red queen reigns in the kingdom of RNA viruses. Proceedings of the National Academy of Sciences (USA) 91: 4821-4824.
Wilson JJ, Polyak SJ, Day TD, Gretch DR: (1995): Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing. Journal of General Virology 76: 1763-1771.
Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C: (1994): Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. Journal of General Virology 75: 1361-1369.
Pawlotsky JM, Dhumeaux D, Bagot M: (1995a) Hepatitis C virus in dermatology. A review. Archives of Dermatology 131: 1185-1193.
Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sanchez-Pescador R: (1996): Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. Journal of Clinical Microbiology 34: 901-907.
Gonzalez-Peralta RP, Qian KP, She JY, Davis GL, Ohno T, Mizokami M, Lau JYN: (1996): Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. Journal of Medical Virology 49: 242-247.
Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, Kaneshige T, Igimi H, Kamada T, Uchida K: (1995): Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 108: 789-795.
Sakamoto N, Enomoto N, Kurosaki M, Asahina Y, Maekawa S, Koizumi K, Sakuma I, Murakami T, Marumo F, Sato C: (1995): Comparison of the hypervariable region of hepatitis C virus genomes in plasma and liver. Journal of Medical Virology 46: 7-11.
Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, van Heuverswyn H, Maertens G: (1993): Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. Journal of General Virology 74: 1093-1102.
Kumar U, Monjardino J, Thomas HC: (1994): Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106: 1072-1075.
1995a; 131
1986; 315
1989; 5
1990; 10
1996b; 174
1995b; 122
1995; 33
1995; 76
1997
1992; 16
1995; 171
1996; 34
1993; 288
1994; 20
1995; 85
1994; 106
1989; 321
1992; 176
1996a; 40
1995; 46
1995; 22
1995; 108
1993; 74
1995c; 171
1995; 123
1994; 91
1996; 24
1994; 3
1996; 49
1992; 66
1992; 89
1994; 32
1988
1994; 75
Detmer (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB4) 1996; 34
Hopf (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB14) 1990; 10
Martell (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB21) 1992; 66
Clarke (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB3) 1994; 91
Holland (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB12) 1992; 176
Urdea (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB37) 1997
Martinot-Peignoux (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB22) 1995; 22
Sakamoto (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB33) 1995; 46
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB27) 1995a; 131
Weiner (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB38) 1992; 89
Kumar (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB17) 1994; 106
Odeberg (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB24) 1995; 33
Lin (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB18) 1995; 171
Enomoto (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB7) 1994; 75
Mahaney (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB20) 1994; 20
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB29) 1996a; 40
Wilson (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB39) 1995; 76
Alter (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB2) 1995; 85
Eigen (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB6) 1988
Sekiya (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB34) 1993; 288
Kanazawa (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB15) 1994; 20
Okada (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB25) 1992; 16
Gonzalez-Peralta (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB9) 1996; 49
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB31) 1995b; 122
Hoofnagle (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB13) 1986; 315
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB30) 1996b; 174
Lu (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB19) 1995; 76
Orita (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB26) 1989; 5
Koizumi (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB16) 1995; 22
Farci (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB8) 1994; 91
Shindo (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB35) 1996; 24
Moribe (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB23) 1995; 108
Gretch (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB10) 1997
Stuyver (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB36) 1993; 74
Alter (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB1) 1989; 321
Gumber (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB11) 1995; 123
Duarte (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB5) 1994; 3
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB28) 1994; 32
Pawlotsky (10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB32) 1995c; 171
References_xml – volume: 20
  start-page: 1405
  year: 1994
  end-page: 1411
  article-title: Genotypic analysis of hepatitis C virus in American patients
  publication-title: Hepatology
– volume: 20
  start-page: 1121
  year: 1994
  end-page: 1130
  article-title: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
  publication-title: Hepatology
– volume: 321
  start-page: 1494
  year: 1989
  end-page: 1500
  article-title: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitis
  publication-title: New England Journal of Medicine
– volume: 34
  start-page: 901
  year: 1996
  end-page: 907
  article-title: Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched‐DNA technology
  publication-title: Journal of Clinical Microbiology
– volume: 76
  start-page: 1763
  year: 1995
  end-page: 1771
  article-title: Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing
  publication-title: Journal of General Virology
– volume: 315
  start-page: 1575
  year: 1986
  end-page: 1578
  article-title: Treatment of chronic non‐A, non‐B hepatitis with recombinant human alpha interferon. A preliminary report
  publication-title: New England Journal of Medicine
– start-page: 73
  year: 1997
  end-page: 78
– start-page: 57
  year: 1997
  end-page: 69
– volume: 22
  start-page: 1050
  year: 1995
  end-page: 1056
  article-title: Pretreatment HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C
  publication-title: Hepatology
– volume: 10
  start-page: 69
  year: 1990
  end-page: 76
  article-title: Long term follow‐up of posttransfusion and sporadic chronic hepatitis non‐A, non‐B and frequency of circulating antibodies to hepatitis C virus (HCV)
  publication-title: Journal of Hepatology
– volume: 49
  start-page: 242
  year: 1996
  end-page: 247
  article-title: Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
  publication-title: Journal of Medical Virology
– volume: 76
  start-page: 881
  year: 1995
  end-page: 887
  article-title: Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis
  publication-title: Journal of General Virology
– volume: 85
  start-page: 1681
  year: 1995
  end-page: 1695
  article-title: To C or not to C: these are the questions
  publication-title: Blood
– volume: 106
  start-page: 1072
  year: 1994
  end-page: 1075
  article-title: Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient
  publication-title: Gastroenterology
– volume: 46
  start-page: 7
  year: 1995
  end-page: 11
  article-title: Comparison of the hypervariable region of hepatitis C virus genomes in plasma and liver
  publication-title: Journal of Medical Virology
– volume: 33
  start-page: 1870
  year: 1995
  end-page: 1874
  article-title: Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid‐phase sequencing
  publication-title: Journal of Clinical Microbiology
– volume: 16
  start-page: 619
  year: 1992
  end-page: 624
  article-title: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
  publication-title: Hepatology
– volume: 32
  start-page: 1357
  year: 1994
  end-page: 1359
  article-title: Significance of highly positive c22‐3 “indeterminate” second‐generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third‐generation HCV RIBA
  publication-title: Journal of Clinical Microbiology
– volume: 24
  start-page: 1018
  year: 1996
  end-page: 1023
  article-title: The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
  publication-title: Hepatology
– volume: 171
  start-page: 1607
  year: 1995c
  end-page: 1610
  article-title: Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C
  publication-title: Journal of Infectious Diseases
– volume: 75
  start-page: 1361
  year: 1994
  end-page: 1369
  article-title: Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single‐strand conformation polymorphism analysis
  publication-title: Journal of General Virology
– volume: 288
  start-page: 79
  year: 1993
  end-page: 83
  article-title: Detection of mutant sequences by single‐strand conformation polymorphism analysis
  publication-title: Mutation Research
– volume: 91
  start-page: 7792
  year: 1994
  end-page: 7796
  article-title: Prevention of hepatitis C virus infection in chimpanzees after antibody‐mediated in vitro neutralization
  publication-title: Proceedings of the National Academy of Sciences USA
– volume: 176
  start-page: 1
  year: 1992
  end-page: 20
  article-title: RNA virus populations as quasispecies
  publication-title: Current Topics in Microbiology and Immunology
– volume: 3
  start-page: 201
  year: 1994
  end-page: 214
  article-title: RNA virus quasispecies: significance for viral disease and epidemiology
  publication-title: Infectious Agents and Disease
– volume: 40
  start-page: 320
  year: 1996a
  end-page: 324
  article-title: Effect of alpha interferon (IFN‐a) on 2′‐5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN‐a
  publication-title: Antimicrobial Agents and Chemotherapy
– volume: 22
  start-page: 30
  year: 1995
  end-page: 35
  article-title: Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment
  publication-title: Hepatology
– volume: 89
  start-page: 3468
  year: 1992
  end-page: 3472
  article-title: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants : potential role in chronic HCV infections
  publication-title: Proceedings of the National Academy of Sciences (USA)
– volume: 122
  start-page: 169
  year: 1995b
  end-page: 173
  article-title: Extra‐hepatic immunological manifestations in chronic hepatitis C and hepatitis C virus serotypes
  publication-title: Annals of Internal Medicine
– volume: 91
  start-page: 4821
  year: 1994
  end-page: 4824
  article-title: The red queen reigns in the kingdom of RNA viruses
  publication-title: Proceedings of the National Academy of Sciences (USA)
– volume: 174
  start-page: 1
  year: 1996b
  end-page: 7
  article-title: Factors affecting treatment responses to interferon‐a in chronic hepatitis C
  publication-title: Journal of Infectious Diseases
– volume: 74
  start-page: 1093
  year: 1993
  end-page: 1102
  article-title: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
  publication-title: Journal of General Virology
– volume: 171
  start-page: 1619
  year: 1995
  end-page: 1622
  article-title: Single‐strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells, and their virologic cultures
  publication-title: Journal of Infectious Diseases
– volume: 108
  start-page: 789
  year: 1995
  end-page: 795
  article-title: Hepatitis C viral complexity detected by single‐strand conformation polymorphism and response to interferon therapy
  publication-title: Gastroenterology
– start-page: 211
  year: 1988
  end-page: 245
– volume: 5
  start-page: 874
  year: 1989
  end-page: 879
  article-title: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction
  publication-title: Genomics
– volume: 131
  start-page: 1185
  year: 1995a
  end-page: 1193
  article-title: Hepatitis C virus in dermatology. A review
  publication-title: Archives of Dermatology
– volume: 123
  start-page: 615
  year: 1995
  end-page: 620
  article-title: Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations
  publication-title: Annals of Internal Medicine
– volume: 66
  start-page: 3225
  year: 1992
  end-page: 29
  article-title: Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCgenome distribution
  publication-title: Journal of Virology
– volume: 24
  start-page: 1018
  year: 1996
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB35
  publication-title: Hepatology
  doi: 10.1002/hep.510240507
  contributor:
    fullname: Shindo
– volume: 3
  start-page: 201
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB5
  publication-title: Infectious Agents and Disease
  contributor:
    fullname: Duarte
– volume: 40
  start-page: 320
  year: 1996a
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB29
  publication-title: Antimicrobial Agents and Chemotherapy
  doi: 10.1128/AAC.40.2.320
  contributor:
    fullname: Pawlotsky
– volume: 66
  start-page: 3225
  year: 1992
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB21
  publication-title: Journal of Virology
  doi: 10.1128/JVI.66.5.3225-3229.1992
  contributor:
    fullname: Martell
– volume: 85
  start-page: 1681
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB2
  publication-title: Blood
  doi: 10.1182/blood.V85.7.1681.bloodjournal8571681
  contributor:
    fullname: Alter
– volume: 91
  start-page: 7792
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB8
  publication-title: Proceedings of the National Academy of Sciences USA
  doi: 10.1073/pnas.91.16.7792
  contributor:
    fullname: Farci
– volume: 122
  start-page: 169
  year: 1995b
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB31
  publication-title: Annals of Internal Medicine
  doi: 10.7326/0003-4819-122-3-199502010-00002
  contributor:
    fullname: Pawlotsky
– volume: 75
  start-page: 1361
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB7
  publication-title: Journal of General Virology
  doi: 10.1099/0022-1317-75-6-1361
  contributor:
    fullname: Enomoto
– volume: 74
  start-page: 1093
  year: 1993
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB36
  publication-title: Journal of General Virology
  doi: 10.1099/0022-1317-74-6-1093
  contributor:
    fullname: Stuyver
– volume: 20
  start-page: 1405
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB20
  publication-title: Hepatology
  doi: 10.1002/hep.1840200605
  contributor:
    fullname: Mahaney
– volume: 16
  start-page: 619
  year: 1992
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB25
  publication-title: Hepatology
  doi: 10.1002/hep.1840160302
  contributor:
    fullname: Okada
– volume: 315
  start-page: 1575
  year: 1986
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB13
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJM198612183152503
  contributor:
    fullname: Hoofnagle
– volume: 20
  start-page: 1121
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB15
  publication-title: Hepatology
  doi: 10.1002/hep.1840200504
  contributor:
    fullname: Kanazawa
– volume: 321
  start-page: 1494
  year: 1989
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB1
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJM198911303212202
  contributor:
    fullname: Alter
– volume: 5
  start-page: 874
  year: 1989
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB26
  publication-title: Genomics
  doi: 10.1016/0888-7543(89)90129-8
  contributor:
    fullname: Orita
– volume: 33
  start-page: 1870
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB24
  publication-title: Journal of Clinical Microbiology
  doi: 10.1128/JCM.33.7.1870-1874.1995
  contributor:
    fullname: Odeberg
– volume: 76
  start-page: 1763
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB39
  publication-title: Journal of General Virology
  doi: 10.1099/0022-1317-76-7-1763
  contributor:
    fullname: Wilson
– volume: 49
  start-page: 242
  year: 1996
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB9
  publication-title: Journal of Medical Virology
  doi: 10.1002/(SICI)1096-9071(199607)49:3<242::AID-JMV14>3.0.CO;2-E
  contributor:
    fullname: Gonzalez-Peralta
– volume: 76
  start-page: 881
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB19
  publication-title: Journal of General Virology
  doi: 10.1099/0022-1317-76-4-881
  contributor:
    fullname: Lu
– volume: 32
  start-page: 1357
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB28
  publication-title: Journal of Clinical Microbiology
  doi: 10.1128/JCM.32.5.1357-1359.1994
  contributor:
    fullname: Pawlotsky
– volume: 108
  start-page: 789
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB23
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(95)90452-2
  contributor:
    fullname: Moribe
– volume: 22
  start-page: 30
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB16
  publication-title: Hepatology
  contributor:
    fullname: Koizumi
– volume: 171
  start-page: 1607
  year: 1995c
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB32
  publication-title: Journal of Infectious Diseases
  doi: 10.1093/infdis/171.6.1607
  contributor:
    fullname: Pawlotsky
– volume: 10
  start-page: 69
  year: 1990
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB14
  publication-title: Journal of Hepatology
  doi: 10.1016/0168-8278(90)90075-3
  contributor:
    fullname: Hopf
– volume: 123
  start-page: 615
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB11
  publication-title: Annals of Internal Medicine
  doi: 10.7326/0003-4819-123-8-199510150-00008
  contributor:
    fullname: Gumber
– volume: 89
  start-page: 3468
  year: 1992
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB38
  publication-title: Proceedings of the National Academy of Sciences (USA)
  doi: 10.1073/pnas.89.8.3468
  contributor:
    fullname: Weiner
– volume: 176
  start-page: 1
  year: 1992
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB12
  publication-title: Current Topics in Microbiology and Immunology
  doi: 10.1007/978-3-642-77011-1_1
  contributor:
    fullname: Holland
– start-page: 73
  volume-title: Hepatitis C virus: genetic heterogeneity and viral load
  year: 1997
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB37
  contributor:
    fullname: Urdea
– start-page: 211
  volume-title: RNA genetics, Volume 3: Variability of RNA Genomes
  year: 1988
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB6
  contributor:
    fullname: Eigen
– start-page: 57
  volume-title: Hepatitis C Virus: Genetic Heterogeneity and Viral Load
  year: 1997
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB10
  contributor:
    fullname: Gretch
– volume: 131
  start-page: 1185
  year: 1995a
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB27
  publication-title: Archives of Dermatology
  doi: 10.1001/archderm.1995.01690220091017
  contributor:
    fullname: Pawlotsky
– volume: 46
  start-page: 7
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB33
  publication-title: Journal of Medical Virology
  doi: 10.1002/jmv.1890460103
  contributor:
    fullname: Sakamoto
– volume: 171
  start-page: 1619
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB18
  publication-title: Journal of Infectious Diseases
  doi: 10.1093/infdis/171.6.1619
  contributor:
    fullname: Lin
– volume: 174
  start-page: 1
  year: 1996b
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB30
  publication-title: Journal of Infectious Diseases
  doi: 10.1093/infdis/174.1.1
  contributor:
    fullname: Pawlotsky
– volume: 22
  start-page: 1050
  year: 1995
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB22
  publication-title: Hepatology
  doi: 10.1002/hep.1840220406
  contributor:
    fullname: Martinot-Peignoux
– volume: 106
  start-page: 1072
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB17
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(94)90770-6
  contributor:
    fullname: Kumar
– volume: 288
  start-page: 79
  year: 1993
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB34
  publication-title: Mutation Research
  doi: 10.1016/0027-5107(93)90209-X
  contributor:
    fullname: Sekiya
– volume: 91
  start-page: 4821
  year: 1994
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB3
  publication-title: Proceedings of the National Academy of Sciences (USA)
  doi: 10.1073/pnas.91.11.4821
  contributor:
    fullname: Clarke
– volume: 34
  start-page: 901
  year: 1996
  ident: 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3-BIB4
  publication-title: Journal of Clinical Microbiology
  doi: 10.1128/JCM.34.4.901-907.1996
  contributor:
    fullname: Detmer
SSID ssj0008922
Score 1.9115201
Snippet HCV exists within its host as pools of related genetic variants referred to as quasispecies. The hypervariable region 1 (HVR1) of the E2 envelope gene is...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 256
SubjectTerms Adolescent
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Base Sequence
Biological and medical sciences
Female
genetic complexity
Genetic Variation
Hepacivirus - drug effects
Hepacivirus - genetics
hepatitis C virus
Hepatitis C, Chronic - drug therapy
Human viral diseases
Humans
hypervariable region 1
Infectious diseases
interferon alpha
Interferon-alpha - therapeutic use
Male
Medical sciences
Middle Aged
Molecular Sequence Data
Pharmacology. Drug treatments
Polymerase Chain Reaction
Polymorphism, Single-Stranded Conformational
quasispecies
Sequence Alignment
Sequence Homology, Nucleic Acid
Viral diseases
Viral Envelope Proteins - genetics
Viral hepatitis
Title Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
URI https://api.istex.fr/ark:/67375/WNG-X330FHR8-F/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291096-9071%28199804%2954%3A4%3C256%3A%3AAID-JMV4%3E3.0.CO%3B2-3
https://www.ncbi.nlm.nih.gov/pubmed/9557291
https://search.proquest.com/docview/16393286
https://search.proquest.com/docview/79812615
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1fb9MwELemIU288H-iwMAPDLUP6ZLYiZMyIY2w0k7qJhXW9c1yYkerhlLUtGjsq_Cx-ELcxU1HYYgXJKRWav75at_Zvl989zMhL02cA65QxlFeoB0ec89RLAwdVWVhZrERGnOHB8dh75QfjYPxBrmqc2EsP8TqhRv2jGq8xg6u0nLvmjQUHLAP_aQPgNkDN9wBkOchtRHAB5fv4uoVqBi-Cczp8As-B_13ztFgBOcOWdttJye77K3vIFEo8vChPzW8Zp6KYrsAAQOJA1NYsEX2l6L3mii2tRLatCJbAe_wfRDW6dSC3lgxr0HI2qx3CxV4iVGYqgRF5HYHjZtc3HWPuZryunfJt7qxbKTLRXsxT9vZ1S88kv-nNe-RO0tPmh5Y079PNkzxgGwNlrECD8l3ZNSGa7SKmjeXADfoNKfg8NJzAN-4JdIE88Yo7k0xLahHm73R0GvhTecGA83nk5Im9MtktijhWjJqdWi_3tOFwhNYVLZOeF1LqGPcCqoKDRKqQGRT0vmUIkHHLDczvPYpV9RmwH2F83RJcltSfDsORVe8xT__mUfktHv4Mek5yy0snIwJxh2dpmFmgsgVvlaAFZnSsYoU56mCZs49LbIw9bNcBKFSPFRhIFKt3cyNNIymOmLbZLOYFuYxoUzHWvk8M64WPAfUGvuREkyLHLqVFmGDDGoTk58tU4m0nNS-lKhbDDYIJWpWWr3KgEsuQaNSgjYlalMy6crkRPqSNciryk5XhanZBUYBikCeHb-XY8bcbm8YyW6D7KwZ8uoBmCoi7rsN8qI2bAljFy5IqcJMF6UELADwIQr_fIeIwQGF7tcg27ZHrAqPgwBwoQe1rsz6tyr_pcY3VLg6fvKPy3tKbtssVoz1ekY257OF2QE3dp4-rwacH-5Hf1w
link.rule.ids 315,786,790,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1fb9MwELfGJg1e-D9RYMwPDLUP6ZLY-VcmpJGttGPtpLGVvllO7GjVUIqaFg34KnwrvhB3cdNRGOIFCamVmjjx1T7f-c6--5mQ5zrKwK-Q2pKOpywecceSzPctWWZhppEOFOYO9_p-54wfDr3hCvla5cIYfIjFghtKRqmvUcBxQXrnCjUULLB33bgLHrMDdrgFXp6D2EbgP9h8G7evgMfwjWFSh1_w2evuW4e9Adw7YE27GR9vs9euxW6QNdAWHkr1_skV9lQYmS0IUCUWTGLeOtmd096pI93Ggmrd0Gx4vMV3gVqrVVF6Zei8BCpL894asvAS4zBlAazIzBka1xm5yzZzOem175BvVXeZWJeL5myaNNMvvyBJ_qf-vEtuz41pumdG_z2yovP7ZL03Dxd4QL4jqDaU0TJwXl-Cx0HHGQWbl56D_42nIo0wdYzi8RTjnDq03hmcOA186FxjrPl0VNCYfhpNZgWUxYNGi3arY10ovIFVpcuY1xWFKswtpzJXQKGMRdYFnY4pYnRMMj3Bsg-ZpCYJ7jPcp3Oc24LiAjlUXUIX__xnHpKz9sFp3LHmp1hYKQsYt1SS-Kn2QjtwlQR3kUkVyVBynkjo5sxRQeonbpoFni8l96XvBYlSdmqHChSqCtkGWc3HuX5EKFORki5Pta0CnoHjGrmhDJgKMpAsFfg10qvGmPhowEqEgaV2hUDeYryBL5CzwvBVeFxwARwVArgpkJuCCVvEx8IVrEZelAN1UZmcXGAgYOCJ9_03YsiY3e6chKJdI5tLI3nxAswWIXftGtmqRrYA9YV7UjLX41khwB0ADyL0__xEEIENCvJXIxtGJBaVR54HrqEDrS7H9W9N_kuLr2lwef34H9e3RW52TntH4qjbf_uE3DJJrRj69ZSsTiczvQlW7TR5VmqfH_Epg3w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGJlW8cJ8oMOYHhtqHdEns3MqENNKVdtAObaz0zXJiR6uG0qkXNPZX-Fn8Ic6Jm47CEC9ISK3U3Hxqn2P7fPE5nwl5oaMMcIXUlnQ8ZfGIO5Zkvm_JIgszjXSgMHe41_c7p_xw6A3XyFWZC2P4IZYv3LBnFOM1dvALle1ek4aCA3bSjbsAmB1wwy0AeQ5SGwF8sPkOrl6BiuEbw5wOv-Cz321Zh70BnDtgDbsRH-2wN67FbpEN7jMXgVvr-Jp6KozMCgSMJBbMYV6F7C1k79ZQbn0ptWZk1j3e5HsgrdksJb02cl6BlJVpbwM1eIlhmHIKmsjMFho3-birLnMx57Xvkm9la5lQl_PGfJY00qtfiCT_T3PeI3cWrjTdN7Z_n6zp_AGp9BbBAg_Jd6TUhmu0CJvXl4A36Dij4PHSM0DfuCfSCBPHKG5OMc6pQ2udwbFTx5vONEaaz0ZTGtMvo8l8CtfiQb1Ju-WmLhSewKLSVcbrUkIZ5JZTmSuQUEQi6ymdjSkydEwyPcFrnzNJTQrcVzhPFyy3U4qvx6Hogrj45z_ziJy2Dz7GHWuxh4WVsoBxSyWJn2ovtANXSQCLTKpIhpLzREIzZ44KUj9x0yzwfCm5L30vSJSyUztUMJyqkG2S9Xyc68eEMhUp6fJU2yrgGcDWyA1lwFSQQb9SgV8lvdLExIWhKhGGlNoVAnWL0Qa-QM0Ko1fhccEFaFQI0KZAbQombBEfCVewKnlZ2OmyMDk5xzDAwBOf-m_FkDG73TkORbtKtlYMefkAzBUhd-0q2S4NW8DghStSMtfj-VQAGAD8EPp_viOIwAOF7lclm6ZHLAuPPA-AoQO1Lsz6tyr_pcY3VLg4fvKPy9smlQ-ttnjf7b97Sm6bjFaM-3pG1meTud4Cl3aWPC_Gnh_ReoIr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+complexity+of+the+hypervariable+region+1+%28HVR1%29+of+hepatitis+C+virus+%28HCV%29%3A+Influence+on+the+characteristics+of+the+infection+and+responses+to+interferon+alfa+therapy+in+patients+with+chronic+hepatitis+C&rft.jtitle=Journal+of+medical+virology&rft.au=Pawlotsky%2C+Jean-Michel&rft.au=Pellerin%2C+Muriel&rft.au=Bouvier%2C+Magali&rft.au=Roudot-Thoraval%2C+Fran%C3%A7oise&rft.date=1998-04-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=54&rft.issue=4&rft.spage=256&rft.epage=264&rft_id=info:doi/10.1002%2F%28SICI%291096-9071%28199804%2954%3A4%3C256%3A%3AAID-JMV4%3E3.0.CO%3B2-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002__SICI_1096_9071_199804_54_4_256__AID_JMV4_3_0_CO_2_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon